- idUS
- Listar por autor
Listar por autor "Ríos Herranz, Eduardo"
Mostrando ítems 1-5 de 5
-
Artículo
Case-Control Analysis of the Impact of Anemia on Quality of Life in Patients with Cancer: A Qca Study Analysis
Barca-Hernando, María; Muñoz-Martín, Andrés J.; Ríos Herranz, Eduardo; García-Escobar, Ignacio; Beato, Carmen; Font, Carme; Otero Candelera, Remedios; Jara-Palomares, Luis (MDPI, 2021)Anemia is a common condition in cancer patients and is associated with a wide variety of symptoms that impair quality of ...
-
Artículo
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
Jiménez Cortegana, Carlos; Palazón Carrión, Natalia; Martín García-Sancho, Alejandro; Nogales-Fernández, Esteban; Carnicero-González, Fernando; Ríos Herranz, Eduardo; Sánchez Margalet, Víctor; Cruz Merino, Luis de la (BMJ, 2021)Background The search for immunological markers with ability of predicting clinical outcome is a priority in lymphomas, ...
-
Artículo
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
Palazón Carrión, Natalia; Martín García-Sancho, Alejandro; Nogales-Fernández, Esteban; Jiménez Cortegana, Carlos; Carnicero-González, Fernando; Ríos Herranz, Eduardo; Sánchez Margalet, Víctor; Rueda Domínguez, Antonio; Cruz Merino, Luis de la (AMER ASSOC CANCER RESEARCH, 2022)Purpose: New therapeutic options are needed in relapsed/refrac tory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide ...
-
Artículo
Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain
Martínez, Carmen; Corral Carpio, Cecilia; Heras, Inmaculada; Ríos Herranz, Eduardo; Buch, Joan; Gutierrez, Antonio; García-Sanz, Ramón (Elsevier Science Inc, 2022)Clinical trials have shown that nivolumab has remarkable activity against relapsed/refractory classical Hodgkin lymphoma ...
-
Artículo
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
Abrisqueta, Pau; Loscertales, Javier; Terol, María José; Ramírez Payer, Ángel; Ortiz, Macarena; Pérez, Inmaculada; Ríos Herranz, Eduardo; Villanueva, Miguel (Elsevier, 2021)Ibrutinib demonstrated robust efficacy, regardless of high-risk features, in previously untreated or relapsed/refractory ...